Liposomal Amiodarone augments anti-arrhythmic effects and reduces Hemodynamic adverse effects in an ischemia/ reperfusion rat model

Cardiovascular Drugs and Therapy

Volumn 27, Issue 2, 2013, Pages 125-132

  Takahama, Hiroyuki ^b,e   Shigematsu, Hirokazu ^c   Asai, Tomohiro ^c   Matsuzaki, Takashi ^a   Sanada, Shoji ^a   Fu, Hai Ying ^a   Okuda, Keiji ^a   Yamato, Masaki ^a   Asanuma, Hiroshi ^d   Asano, Yoshihiro ^a   Asakura, Masanori ^b   Oku, Naoto ^c   Komuro, Issei ^a   Kitakaze, Masafumi ^b   Minamino, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e MAYO CLINIC   (United States)

Author keywords

Amiodarone; Ischemia; Lethal arrhythmia; Liposome; Reperfusion

Indexed keywords

AMIODARONE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG POTENCY; DRUG TISSUE LEVEL; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART RATE; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DISEASE MODELS, ANIMAL; HEMODYNAMICS; LIPOSOMES; MALE; MYOCARDIAL REPERFUSION INJURY; NANOPARTICLES; RATS; RATS, WISTAR;

EID: 84878299598     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6437-6     Document Type: Article

References (30)

1. Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Hear Rhythm. 2011;8:1963-8.
2. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
3. Vassallo P, Trohman RG. Prescribing amiodarone: An evidencebased review of clinical indications. JAMA. 2007;298:1312-22.
4. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients life-Threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Muticenter Investigators Group. Circulation. 1995;92:3264-72.
5. Podrid PJ. Amiodarone; reevaluation of an old drug. Ann Intern Med. 1995;122:689-700.
6. Shiga T, Tanaka T, Irie S, Hagiwara N, Kasanuki H. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Hear Vessel. 2011;26:274-81.
7. Wenzel V, Russo SG, Arntz HR, et al. [Comments on the 2010 guidelines on cardiopulmonary resuscitation of the European Resuscitation Council.]. Anaesthesist. 2010.
8. Elizari MV, Martínez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J. 2000;21:198-205.
9. Hu K, Gaudron P, Ertl G. Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. J Cardiovasc Pharmacol. 2004;44:627-30.
10. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MS. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv. 2009;6:599-612.
11. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-38.
12. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592-9.
13. Horwitz LD, Kaufman D, Keller MW, Kong Y. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation. 1994;90:2439-47.
14. Dauber IM, VanBenthuysen KM, McMurtry IF, et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res. 1990;66:986-98.
15. Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231-7.
16. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53:709-17.
17. Riva E, Hearse DJ. Anti-arrhythmic effects of amiodarone and desethylamiodarone on malignant ventricular arrhythmias arising as a consequence of ischaemia and reperfusion in the anaesthetised rat. Cardiovasc Res. 1989;23:331-9.
18. Canyon SJ, Dobson GP. Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am J Physiol Heart Circ Physiol. 2004;287:H1286-95.
19. Plomp TA, Wiersinga WM, Maes RA. Tissue distribution of amiodarone and desethylamiodarone in rats after repeated oral administration of various amiodarone dosages. Arzneimittelforschung. 1985;35:1805-10.
20. Feige JN, Sage D, Wahli W, Desvergne B, Gelman L. PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-Trhoughs. Microsc Res Tech. 2005;68:51-8.
21. Opitz CF, Mitchell GF, Pfeffer MA, Pfeffer JM. Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 1995;92:253-61.
22. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-7.
23. Theodossiou TA, Galanou MC, Paleos CM. Novel amiodaronedoxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells. J Med Chem. 2008;51:6067-74.
24. Elhasi S, Astaneh R, Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur J Pharm Biopharm. 2007;65:406-13.
25. Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I. Short- and long-Term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation. 2001;9:1317-24.
26. Kishida S, Nakajima T, Ma J, et al. Amiodarone and Ndesethylamiodarone enhance endothelial nitric oxide production in human endothelial cells. Int Heart J. 2006;47:85-93.
27. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 1999;100:690-2.
28. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharamacol. 1991;31:1061-9.
29. Sakamoto J, Miura T, Tsuchida A, Fukuma T, Hasegawa T, Shimamoto K. Reperfusion arrhythmias in the murine heart: their characteristics and alteration after ischemic preconditioning. Basic Res Cardiol. 1999;94:489-95.
30. Tzivoni D, Keren A, Granot H, Gottlieb S, Benhorin J, Stern S. Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal's angina. Am Heart J. 1983;105:323-5.